The Burden of Respiratory Syncytial Virus Infection in the Young

Respiratory syncytial virus (RSV) causes seasonal epidemics during the winter and wet seasons, particularly in young children. Although there is one drug available for prophylaxis, palivizumab, it is indicated for high-risk children only. Therefore a vaccine is urgently needed. This book provides an...

Full description

Bibliographic Details
Main Author: Resch, Bernhard
Format: eBook
Language:English
Published: IntechOpen 2019
Subjects:
Online Access:
Collection: Directory of Open Access Books - Collection details see MPG.ReNa
LEADER 01700nma a2200313 u 4500
001 EB001991142
003 EBX01000000000000001154044
005 00000000000000.0
007 cr|||||||||||||||||||||
008 210512 ||| eng
020 |a 9781789846423 
020 |a 9781789846430 
020 |a 9781839622526 
020 |a intechopen.78206 
100 1 |a Resch, Bernhard 
245 0 0 |a The Burden of Respiratory Syncytial Virus Infection in the Young  |h Elektronische Ressource 
260 |b IntechOpen  |c 2019 
300 |a 1 electronic resource (108 p.) 
653 |a Respiratory medicine 
653 |a Dermatology / bicssc 
700 1 |a Resch, Bernhard 
041 0 7 |a eng  |2 ISO 639-2 
989 |b DOAB  |a Directory of Open Access Books 
500 |a Creative Commons (cc), https://creativecommons.org/licenses/by/3.0/ 
028 5 0 |a 10.5772/intechopen.78206 
856 4 0 |u https://mts.intechopen.com/storage/books/8250/authors_book/authors_book.pdf  |7 0  |x Verlag  |3 Volltext 
856 4 2 |u https://directory.doabooks.org/handle/20.500.12854/67053  |z DOAB: description of the publication 
082 0 |a 610 
520 |a Respiratory syncytial virus (RSV) causes seasonal epidemics during the winter and wet seasons, particularly in young children. Although there is one drug available for prophylaxis, palivizumab, it is indicated for high-risk children only. Therefore a vaccine is urgently needed. This book provides an overview of RSV and discusses its incidence and presentation in different populations, including preterm infants and children with congenital heart disease. It also discusses future strategies for RSV prophylaxis and developments in and barriers to creating a viable vaccine.